Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors

Therapeutic Delivery

Volumn 1, Issue 2, 2010, Pages 289-305

  Sarin, Hemant ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CATION; DENDRIMER; DOXORUBICIN; GADOLINIUM PENTETATE; LIPID; LIPOSOME; LOBRADIMIL; LOMUSTINE; NANOPARTICLE; RHODAMINE B; TEMOZOLOMIDE; VINBLASTINE; VINCRISTINE;

CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CAPILLARY WALL; CELL MEMBRANE PERMEABILITY; CENTRAL NERVOUS SYSTEM TUMOR; CHANNEL GATING; CLINICAL EFFECTIVENESS; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG LABELING; DRUG MECHANISM; DRUG PENETRATION; DRUG RELEASE; DRUG TRANSPORT; DRUG TUMOR LEVEL; GLIOMA; GLYCOCALYX; HUMAN; LIPID SOLUBILITY; MACROMOLECULE; MICROVASCULATURE; NONHUMAN; PARENCHYMA; PARTICLE SIZE; PERMEABILITY BARRIER; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SPINAL CORD; SURFACE CHARGE;

EID: 78649390167     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.22     Document Type: Review

References (200)

1. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114(2), 97 (2007).
2. Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322(8), 494-500 (1990). (Pubitemid 20067825)
3. Weil RJ, Lonser RR, DeVroom HL, Wanebo JE, Oldfield EH. Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J. Neurosurg. 98(1 Suppl.), 95-105 (2003). (Pubitemid 36050452)
4. Moss JM, Choi CY, Adler JR Jr, Soltys SG, Gibbs IC, Chang SD. Stereotactic radiosurgical treatment of cranial and spinal hemangioblastomas. Neurosurgery 65(1), 79-85 (2009).
5. Wohrer A, Waldhor T, Heinzl H et al. The Austrian brain tumour registry: a cooperative way to establish a population-based brain tumour registry. J. Neurooncol. 95(3), 401-411 (2009).
6. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol. 22(14), 2865-2872 (2004). (Pubitemid 41079905)
7. Eichler AF, Plotkin SR. Brain metastases. Curr. Treat. Options Neurol. 10(4), 308-314 (2008).
8. Brown M, Schrot R, Bauer K, LeTendre D. Incidence of first primary central nervous system tumors in California, 2001-2005. J. Neurooncol. 94(2), 263-273 (2009).
9. Melisko ME, Glantz M, Rugo HS. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat. Clin. Pract. Oncol. 6(1), 25 (2009).
10. Ranjan T, Abrey LE. Current management of metastatic brain disease. Neurotherapeutics 6(3), 598 (2009).
11. Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J. Neurooncol. 70(2), 217-228 (2004). (Pubitemid 39545733)
12. Laws ER, Parney IF, Huang W et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the glioma outcomes project. J. Neurosurg. 99(3), 467-473 (2003). (Pubitemid 37040405)
13. Bidros DS, Liu JK, Vogelbaum MA. Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol. 6(1), 117-125 (2010).
14. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Chemotherapeutic wafers for high grade glioma. In: Cochrane Database of Systematic Reviews. John Wiley and Sons, Ltd, NY, USA (2010).
15. Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert Rev. Neurother. 9(10), 1519-1527 (2009).
16. Brem SS, Bierman PJ, Black P et al. Central nervous system cancers: clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw.6(5), 456-504 (2008). (Pubitemid 351754244)
17. Anderson E, Grant R, Lewis SC, Whittle IR. Randomized Phase III controlled trials of therapy in malignant glioma: where are we after 40 years? British J. Neurosurg. 22(3), 339-349 (2008). (Pubitemid 351878617)
18. Muldoon LL, Soussain C, Jahnke K et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol. 25(16), 2295-2305 (2007). (Pubitemid 46954658)
19. Hildebrand J, Gorlia T, Kros JM et al. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European organisation for research and treatment of cancer Phase III study (EORTC study 26882). Eur. J. Cancer 44(9), 1210-1216 (2008).
20. Grundy RG, Wilne SH, Robinson KJ et al. Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial. Eur. J. Cancer 46(1), 120-133 (2010).
21. Nicolaides T, Tihan T, Horn B, Biegel J, Prados M, Banerjee A. High-dose chemotherapy and autologous stem cell rescue for atypical teratoid/rhabdoid tumor of the central nervous system. J. Neurooncol. 98(1), 117-123 (2009).
22. Van Genugten JAB, Leffers P, Baumert BG, Tjon-A-Fat H, Twijnstra A. Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. J. Neurooncol. 96(2), 249-257 (2010).
23. De Witt Hamer PC. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro. Oncol. 12(3), 304-316 (2010).
24. Fangusaro J. Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. J. Child Neurol. 24(11), 1409-1417 (2009).
25. Von Holst H, Knochenhauer E, Blomgren H et al. Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas. Acta Neurochir. 104(1-2), 13-16 (1990). (Pubitemid 20202089)
26. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459 (2009).
27. Levin VA, Landahl HD, Freeman Dove MA. The application of brain capillary permeability coefficient measurements to pathological conditions and the selection of agents which cross the blood brain barrier. J. Pharmacokinet. Biopharm. 4(6), 499 (1976).
28. Sarin H, Kanevsky A, Wu H et al. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J. Transl. Med. 6(80) (2008).
29. Sarin H. Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. J. Transl. Med. 7, 77 (2009).
30. Vick NA, Khandekar JD, Bigner DD. Chemotherapy of brain tumors. The blood-brain barrier' is not a factor. Arch. Neurol. 34(9), 523 (1977).
31. Maeda H, Matsumoto T, Konno T, Iwai K, Ueda M. Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on SMANCS. J. Protein Chem. 3(2), 181-193 (1984). (Pubitemid 14046603)
32. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J. Natl Cancer Inst. 99(19), 1441-1454 (2007).
33. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6, 559-593 (1987).
34. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc. Res. 37(1), 77 (1989).
35. Casley-Smith JR. The role of the endothelial intercellular junctions in the functioning of the initial lymphatics. Angiologica 9(2), 106 (1972).
36. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 60(16), 4324-4327 (2000). (Pubitemid 32103603)
37. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 48(24 Part 1), 7022-7032 (1988). (Pubitemid 19013976)
38. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64(11), 3731-3736 (2004). (Pubitemid 38697278)
39. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 67(6), 2729-2735 (2007). (Pubitemid 46548961)
40. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58-62 (2005). (Pubitemid 40093472)
41. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an antivascular endothelial growth factor/ vascular permeability factor antibody. Proc. Natl Acad. Sci. USA 93(25), 14765-14770 (1996). (Pubitemid 26419043)
42. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Prac. Oncol. 3(1), 24-40 (2006). (Pubitemid 43108832)
43. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin™) as treatment of recurrent glioblastoma multiforme. Oncologist 14(11), 1131-1138 (2009).
44. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009).
45. Verhoeff JJC, Lavini C, van Linde ME et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann. Oncol. DOI: 10.1093/annonc/mdp591(2010) (Epub ahead of print).
46. Greig NH, Soncrant TT, Shetty HU, Momma S, Smith QR, Rapoport SI. Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemother. Pharmacol. 26(4), 263 (1990).
47. Toth K, Vaughan M, Peress N, Slocum H, Rustum Y. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am. J. Pathol. 149(3), 853-858 (1996). (Pubitemid 26334169)
48. Schaich M, Kestel L, Pfirrmann M et al. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann. Oncol. 20(1), 175-181 (2009).
49. Sarkaria JN, Kitange GJ, James CD et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin. Cancer Res. 14(10), 2900-2908 (2008).
50. Toth K, Vaughan MM, Schwartz G et al. Expression of the MRP and MDRI multidrug resistance gene products in 160 untreated human carcinomas studied by immunohistochemical methods in formalin-paraffin sections. Int. J. Surg. Pathol. 6(3), 145-154 (1998). (Pubitemid 28357195)
51. Szakacs G, Annereau JP, Lababidi S et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6(2), 129-137 (2004). (Pubitemid 39485685)
52. Sarin H, Kanevsky AS, Fung SH et al. Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. J. Transl. Med. 7, 33 (2009).
53. Hurria A, Lichtman SM. Clinical pharmacology of cancer therapies in older adults. Br. J. Cancer 98(3), 517-522 (2008). (Pubitemid 351214530)
54. Jen JF, Cutler DL, Pai SM et al. Population pharmacokinetics of temozolomide in cancer patients. Pharm. Res. 17(10), 1284-1289 (2000).
55. Levin VA, Kabra PA, Freeman-Dove MA. Relationship of 1,3-bis(2- chloroethyl)-1- nitrosourea (BCNU) and 1-(2-chloroethyl)- 3-cyclohexyl-1- nitrosourea (CCNU) pharmacokinetics of uptake, distribution, and tissue/plasma partitioning in rat organs and intracerebral tumors. Cancer Chemother. Pharmacol. 1(4), 233 (1978).
56. Levin VA, Kabra P. Effectiveness of the nitrosoureas as a function of their lipid solubility in the chemotherapy of experimental rat brain tumors. Cancer Chemother. Rep. 58(6), 787 (1974).
57. Sarin H. Effective transvascular delivery of chemotherapy into cancer cells with imageable nanoparticles in the 7-10 nanometer size range. In:Current Advances in the Medical Application of Nanotechnology. Slevin M (Ed), eBentham Books (2010) (In Press).
58. Sarin H, Kanevsky A, Wu H et al. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J. Transl. Med. 7(51) DOI: 10.1186/1479-5876-7-51 (2009).
59. Folkman J, Klagsbrun M. Angiogenic factors. Science 235(4787), 442-447 (1987). (Pubitemid 17009577)
60. Roberts WG, Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res. 57(4), 765-772 (1997). (Pubitemid 27085664)
61. Roberts WG, Delaat J, Nagane M, Huang S, Cavenee WK, Palade GE. Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am. J. Pathol. 153(4), 1239-1248 (1998). (Pubitemid 28465847)
62. Bayliss LE, Kerridge PMT, Russell DS. The excretion of protein by the mammalian kidney. J. Physiol. 77(4), 386-398 (1933).
63. Vorbrodt AW. Ultracytochemical characterization of anionic sites in the wall of brain capillaries. J. Neurocytol. 18(3), 359-368 (1989). (Pubitemid 19147403)
64. Schmidley JW, Wissig SL. Anionic sites on the luminal surface of fenestrated and continuous capillaries of the CNS. Brain Res. 363(2), 265-271 (1986). (Pubitemid 16146274)
65. Brightman MW. Morphology of blood-brain interfaces. Exp. Eye Res. 25(Suppl), 1-25 (1977). (Pubitemid 8205025)
66. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol. 40(3), 648-677 (1969).
67. Vick NA, Bigner DD. Microvascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood-brain barrier function. J. Neurol. Sci. 17, 29-39 (1972).
68. Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J. Angiogenes. Res. (2010) (In Press).
69. Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflugers Arch. 440(5), 653-666 (2000).
70. Vink H, Duling BR. Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ. Res. 79(3), 581-589 (1996). (Pubitemid 26276918)
71. Squire JM, Chew M, Nneji G, Neal C, Barry J, Michel C. Quasi-periodic substructure in the microvessel endothelial glycocalyx: a possible explanation for molecular filtering? J. Struct. Biol. 136(3), 239-255 (2001).
72. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 60(16), 4440-4445 (2000). (Pubitemid 32103623)
73. Gabizon A, Chisin R, Amselem S et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br. J. Cancer 64(6), 1125-1132 (1991).
74. Triguero D, Buciak JB, Yang J, Pardridge WM. Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared with native protein. Proc. Natl Acad. Sci. USA 86(12), 4761-4765 (1989). (Pubitemid 19164629)
75. Weinbaum S, Zhang X, Han Y, Vink H, Cowin SC. Mechanotransduction and flow across the endothelial glycocalyx. Proc. Natl Acad. Sci. USA 100, 7988-7995 (2003). (Pubitemid 36760082)
76. Fenstermacher JD, Johnson JA. Filtration and reflection coefficients of the rabbit blood-brain barrier. Am. J. Physiol. 211(2), 341-346 (1966).
77. Sorensen SC. The permeability to small ions of tight junctions between cerebral endothelial cells. Brain Res. 70(1), 174-178 (1974).
78. Jain R, Ellika SK, Scarpace L et al. Quantitative estimation of permeability surface-area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade. Am. J. Neuroradiol. 29(4), 694-700 (2008). (Pubitemid 351571548)
79. Ludemann L, Grieger W, Wurm R, Wust P, Zimmer C. Quantitative measurement of leakage volume and permeability in gliomas, meningiomas and brain metastases with dynamic contrast-enhanced MRI. Magn. Reson. Imaging 23(8), 833 (2005).
80. Provenzale JM, Wang GR, Brenner T, Petrella JR, Sorensen AG. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. Am. J. Roentgenol. 178(3), 711 (2002).
81. Leblond CP, Inoue S. Structure, composition, and assembly of basement membrane. Am. J. Anat. 185(4), 367-390 (1989). (Pubitemid 19213501)
82. Charonis AS, Wissig SL. Anionic sites in basement membranes. Differences in their electrostatic properties in continuous and fenestrated capillaries. Microvasc. Res. 25(3), 265-285 (1983). (Pubitemid 13120308)
83. Terayama N, Terada T, Nakanuma Y. An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue. Histopathology 29(1), 37-43 (1996). (Pubitemid 26232520)
84. Carlson EC, Audette JL, Veitenheimer NJ, Risan JA, Laturnus DI, Epstein PN. Ultrastructural morphometry of capillary basement membrane thickness in normal and transgenic diabetic mice. Anat. Rec. A Discov. Mol. Cell Evol. Biol. 271A(2), 332-341 (2003). (Pubitemid 37238352)
85. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 163(5), 1801-1815 (2003). (Pubitemid 37310012)
86. Ludatscher RM, Gellei B, Barzilai D. Ultrastructural observations on the capillaries of human thyroid tumours. J.Pathol. 128(2), 57-62 (1979). (Pubitemid 9250782)
87. Muldoon LL, Pagel MA, Kroll RA, Roman-Goldstein S, Jones RS, Neuwelt EA. A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery. Am. J. Neuroradiol. 20(2), 217-222 (1999). (Pubitemid 30418701)
88. Shibata S. Ultrastructure of capillary walls in human brain tumors. Acta Neuropathol. 78(6), 561-571 (1989). (Pubitemid 19251310)
89. Wilson CB, Gutin P, Boldrey EB. Single agent chemotherapy of brain tumors. A five year review. Arch. Neurol. 33(1), 739-744 (1976).
90. Young CW, Burchenal JH. Cancer chemotherapy. Annu. Rev. Pharmacol. 11, 369-386 (1971).
91. Fewer D, Wilson CB, Boldrey EB, Enot KJ, Powell MR. The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine. JAMA 222(5), 549-552 (1972).
92. Tentori L, Graziani G. Recent approaches to improve the anti-tumor efficacy of temozolomide. Curr. Med. Chem. 16(2), 245-257 (2009).
93. Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr. Opin. Genet. Dev. 18(1), 87-96 (2008). (Pubitemid 351694452)
94. Schor NF. Pharmacotherapy for adults with tumors of the central nervous system. Pharmacol. Ther. 121, 253-264 (2009).
95. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23(6), 682-684 (1980). (Pubitemid 11237830)
96. Panassaya S, Guocheng W, Barbara RC, Weidong W, Yongfeng W. Skin delivery potency and anti-tumor activities of temozolomide ester prodrugs. Cancer Lett. 244(1), 42-52 (2006).
97. Pappenheimer JR. Passage of molecules through capillary walls. Physiol. Rev. 33(3), 387-423 (1953).
98. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Treat. Rev. 23(1), 35-61 (1997). (Pubitemid 27273454)
99. Speth PAJ, Van Hoesel QGCM, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet. 15(1), 15-31 (1988).
100. Karnovsky MJ. The ultrastructural basis of capillary permeability studied with peroxidase as a tracer. J. Cell Biol. 35(1), 213-236 (1967).
101. Gill P, Litzow M, Buckner J et al. High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. Cancer 112(8), 1805-1811 (2008). (Pubitemid 351536841)
102. Dunkel IJ, Finlay JL. High-dose chemotherapy with autologous stem cell rescue for brain tumors. Crit. Rev. Oncol. Hematol. 41(2), 197-204 (2002). (Pubitemid 34150130)
103. Dunkel IJ, Gardner SL, Garvin JH Jr, Goldman S, Shibata S. High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. J. Clin. Oncol. 12(3), 297-303 (2010).
104. Clarke JL, Iwamoto FM, Sul J et al. Randomized Phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J. Clin. Oncol. 27(23), 3861-3867 (2009).
105. Newton HB. Intra-arterial chemotherapy of primary brain tumors. Curr. Treat. Options Oncol. 6(6), 519-530 (2005). (Pubitemid 43033781)
106. Warren K, Gervais A, Aikin A, Egorin M, Balis FM. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors. Cancer Chemother. Pharmacol. 54(3), 206-212 (2004). (Pubitemid 39141736)
107. Thomas HD, Lind MJ, Ford J, Bleehen N, Calvert AH, Boddy AV. Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. Cancer Chemother. Pharmacol. 45(4), 284 (2000).
108. Decleves X, Amiel A, Delattre JY, Scherrmann JM. Role of ABC transporters in the chemoresistance of human gliomas. Curr. Cancer Drug Targets 6(5), 433 (2006).
109. Moore A, Marecos E, Bogdanov A, Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 214, 568-574 (2000). (Pubitemid 30077721)
110. Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell. Mol. Neurobiol. 20(2), 217 (2000).
111. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res. 61(7), 3027-3032 (2001). (Pubitemid 32691950)
112. Fenstermacher JD, Johnson JA. Filtration and reflection coefficients of the rabbit blood-brain barrier. Am. J. Physiol. 211(2), 341-346 (1966).
113. Sorensen SC. The permeability to small ions of tight junctions between cerebral endothelial cells. Brain Res. 70(1), 174-178 (1974).
114. Jain R, Ellika SK, Scarpace L et al. Quantitative estimation of permeability surface-area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade. Am. J. Neuroradiol. 29(4), 694-700 (2008). (Pubitemid 351571548)
115. Ludemann L, Grieger W, Wurm R, Wust P, Zimmer C. Quantitative measurement of leakage volume and permeability in gliomas, meningiomas and brain metastases with dynamic contrast-enhanced MRI. Magn. Reson. Imaging 23(8), 833 (2005).
116. Provenzale JM, Wang GR, Brenner T, Petrella JR, Sorensen AG. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. Am. J. Roentgenol. 178(3), 711 (2002).
117. Leblond CP, Inoue S. Structure, composition, and assembly of basement membrane. Am. J. Anat. 185(4), 367-390 (1989). (Pubitemid 19213501)
118. Charonis AS, Wissig SL. Anionic sites in basement membranes. Differences in their electrostatic properties in continuous and fenestrated capillaries. Microvasc. Res. 25(3), 265-285 (1983). (Pubitemid 13120308)
119. Terayama N, Terada T, Nakanuma Y. An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue. Histopathology 29(1), 37-43 (1996). (Pubitemid 26232520)
120. Carlson EC, Audette JL, Veitenheimer NJ, Risan JA, Laturnus DI, Epstein PN. Ultrastructural morphometry of capillary basement membrane thickness in normal and transgenic diabetic mice. Anat. Rec. A Discov. Mol. Cell Evol. Biol. 271A(2), 332-341 (2003). (Pubitemid 37238352)
121. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 163(5), 1801-1815 (2003). (Pubitemid 37310012)
122. Ludatscher RM, Gellei B, Barzilai D. Ultrastructural observations on the capillaries of human thyroid tumours. J.Pathol. 128(2), 57-62 (1979). (Pubitemid 9250782)
123. Muldoon LL, Pagel MA, Kroll RA, Roman-Goldstein S, Jones RS, Neuwelt EA. A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery. Am. J. Neuroradiol. 20(2), 217-222 (1999). (Pubitemid 30418701)
124. Shibata S. Ultrastructure of capillary walls in human brain tumors. Acta Neuropathol. 78(6), 561-571 (1989). (Pubitemid 19251310)
125. Wilson CB, Gutin P, Boldrey EB. Single agent chemotherapy of brain tumors. A five year review. Arch. Neurol. 33(1), 739-744 (1976).
126. Young CW, Burchenal JH. Cancer chemotherapy. Annu. Rev. Pharmacol. 11, 369-386 (1971).
127. Fewer D, Wilson CB, Boldrey EB, Enot KJ, Powell MR. The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine. JAMA 222(5), 549-552 (1972).
128. Tentori L, Graziani G. Recent approaches to improve the anti-tumor efficacy of temozolomide. Curr. Med. Chem. 16(2), 245-257 (2009).
129. Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr. Opin. Genet. Dev. 18(1), 87-96 (2008). (Pubitemid 351694452)
130. Schor NF. Pharmacotherapy for adults with tumors of the central nervous system. Pharmacol. Ther. 121, 253-264 (2009).
131. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23(6), 682-684 (1980). (Pubitemid 11237830)
132. Panassaya S, Guocheng W, Barbara RC, Weidong W, Yongfeng W. Skin delivery potency and anti-tumor activities of temozolomide ester prodrugs. Cancer Lett. 244(1), 42-52 (2006).
133. Pappenheimer JR. Passage of molecules through capillary walls. Physiol. Rev. 33(3), 387-423 (1953).
134. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Treat. Rev. 23(1), 35-61 (1997). (Pubitemid 27273454)
135. Speth PAJ, Van Hoesel QGCM, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet. 15(1), 15-31 (1988).
136. Karnovsky MJ. The ultrastructural basis of capillary permeability studied with peroxidase as a tracer. J. Cell Biol. 35(1), 213-236 (1967).
137. Gill P, Litzow M, Buckner J et al. High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. Cancer 112(8), 1805-1811 (2008). (Pubitemid 351536841)
138. Dunkel IJ, Finlay JL. High-dose chemotherapy with autologous stem cell rescue for brain tumors. Crit. Rev. Oncol. Hematol. 41(2), 197-204 (2002). (Pubitemid 34150130)
139. Dunkel IJ, Gardner SL, Garvin JH Jr, Goldman S, Shibata S. High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. J. Clin. Oncol. 12(3), 297-303 (2010).
140. Clarke JL, Iwamoto FM, Sul J et al. Randomized Phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J. Clin. Oncol. 27(23), 3861-3867 (2009).
141. Newton HB. Intra-arterial chemotherapy of primary brain tumors. Curr. Treat. Options Oncol. 6(6), 519-530 (2005). (Pubitemid 43033781)
142. Warren K, Gervais A, Aikin A, Egorin M, Balis FM. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors. Cancer Chemother. Pharmacol. 54(3), 206-212 (2004). (Pubitemid 39141736)
143. Thomas HD, Lind MJ, Ford J, Bleehen N, Calvert AH, Boddy AV. Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. Cancer Chemother. Pharmacol. 45(4), 284 (2000).
144. Decleves X, Amiel A, Delattre JY, Scherrmann JM. Role of ABC transporters in the chemoresistance of human gliomas. Curr. Cancer Drug Targets 6(5), 433 (2006).
145. Moore A, Marecos E, Bogdanov A, Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 214, 568-574 (2000). (Pubitemid 30077721)
146. Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell. Mol. Neurobiol. 20(2), 217 (2000).
147. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res. 61(7), 3027-3032 (2001). (Pubitemid 32691950)
148. Kobayashi H, Reijnders K, English S et al. Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. Clin. Cancer Res. 10(22), 7712-7720 (2004). (Pubitemid 39557536)
149. Yordanov AT, Kobayashi H, English SJ et al. Gadolinium-labeled dendrimers as biometric nanoprobes to detect vascular permeability. J. Mater. Chem. 13(7), 1523-1525 (2003).
150. Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J. Neurosurg. 83(6), 1029-1037 (1995). (Pubitemid 26048143)
151. Sharma US, Sharma A, Chau RI, Straubinger RM. Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm. Res. 14(8), 992-998 (1997). (Pubitemid 27371396)
152. Hau P, Fabel K, Baumgart U et al. Pegylated liposomal doxorubicin - efficacy in patients with recurrent high-grade glioma. Cancer 100(6), 1199-1207 (2004). (Pubitemid 38325948)
153. Fabel K, Dietrich J, Hau P et al. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92(7), 1936-1942 (2001). (Pubitemid 32952514)
154. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42(6), 463-478 (2003). (Pubitemid 37237636)
155. Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm. 354(1-2), 56-62 (2008).
156. Erickson BJ, Campeau NG, Schreiner SA, Buckner JC, O'Neill BP, O'Fallon JR. Triple-dose contrast/magnetization transfer suppressed imaging of non-enhancing' brain gliomas. J. Neurooncol. 60(1), 25-29 (2002). (Pubitemid 35153530)
157. Pluen A, Boucher Y, Ramanujan S et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs subcutaneous tumors. Proc. Natl Acad. Sci. USA 98(8), 4628-4633 (2001). (Pubitemid 32295027)
158. Koyama Y, Hama Y, Urano Y, Nguyen DM, Choyke PL, Kobayashi H. Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin. Cancer Res. 13(10), 2936-2945 (2007). (Pubitemid 46849568)
159. Adams GP, Schier R, McCall AM et al. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61(12), 4750-4755 (2001). (Pubitemid 32691886)
160. Lee CC, Gillies ER, Fox ME et al. A single dose of doxorubicin- functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Natl Acad. Sci. USA 103(45), 16649 (2006).
161. Felgner PL, Gadek TR, Holm M et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl Acad. Sci. USA 84(21), 7413-7417 (1987).
162. Herce HD, Garcia AE. Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc. Natl Acad. Sci. USA 104(52), 20805-20810 (2007).
163. Herve F, Ghinea N, Scherrmann JM. CNS delivery via adsorptive transcytosis. AAPS J. 10(3), 455 (2008).
164. Sugahara KN, Teesalu T, Karmali PP et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328(5981), 1031-1035 (2010).
165. Harrison PM. The structure of apoferritin: molecular size, shape and symmetry from x-ray data. J. Mol. Biol. 6(5), 404-422 (1963).
166. Brightman MW. The distribution within the brain of ferritin injected into cerebrospinal fluid compartments. I. Ependymal distribution. J. Cell Biol. 26(1), 99-123 (1965).
167. Armstrong JK, Wenby RB, Meiselman HJ, Fisher TC. The hydrodynamic radii of macromolecules and their effect on red blood cell aggregation. Biophys. J. 87(6), 4259-4270 (2004). (Pubitemid 39602928)
168. Dellian M, Yuan F, Trubetskoy VS, Torchilin VP, Jain RK. Vascular
169. Yuan F, Dellian M, Fukumura D et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55(17), 3752 (1995).
170. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54(13), 3352-3356 (1994). (Pubitemid 24225946)
171. Campbell RB, Fukumura D, Brown EB et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 62, 6831-6836 (2002). (Pubitemid 35424069)
172. Hobbs SK, Monsky WL, Yuan F et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95, 4607-4612 (1998). (Pubitemid 28207960)
173. Thurston G, McLean JW, Rizen M et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Inv. 101(7), 1401-1413 (1998). (Pubitemid 28166838)
174. MacKay JA, Deen DF, Szoka FC Jr. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res. 1035(2), 139-153 (2005). (Pubitemid 40250186)
175. Kamba T, Tam BYY, Hashizume H et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 290(2), H560-576 (2006).
176. Lutty GA, Hasegawa T, Baba T, Grebe R, Bhutto I, McLeod DS. Development of the human choriocapillaris. Eye 1-8 (2010).
177. Bearer EL, Orci L, Sors P. Endothelial fenestral diaphragms: a quick-freeze, deep-etch study. J. Cell Biol. 100(2), 418-428 (1985). (Pubitemid 15173247)
178. Melamed S, Ben-Sira I, Ben-Shaul Y. Ultrastructure of fenestrations in endothelial choriocapillaries of the rabbit - a freeze-fracturing study. Br. J. Ophthalmol. 64(7), 537-543 (1980). (Pubitemid 10059099)
179. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46(12 I), 6387-6392 (1986). (Pubitemid 17221789)
180. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 71(3), 409 (2009).
181. Kobayashi A, Oda T, Maeda H. Protein binding of macromolecular anticancer agent SMANCS: characterization of poly(styrene-co-maleic acid) derivatives as an albumin binding ligand. J. Bioact. Compat. Polym. 3(4), 319-333 (1988). (Pubitemid 19059729)
182. Oda T, Maeda H. Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its actions by conjugation with lipophilic styrene-maleic acid copolymer. Cancer Res. 47(12), 3206-3211 (1987). (Pubitemid 17082650)
183. Oda T, Sato F, Maeda H. Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH. J. Natl Cancer. Inst. 79(6), 1205-1211 (1987). (Pubitemid 18036723)
184. Wu G, Barth RF, Yang W et al. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconj. Chem. 15(1), 185-194 (2003). (Pubitemid 38165994)
185. Mross K, Niemann B, Massing U et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet™) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother. Pharmacol. 54(6), 514-524 (2004). (Pubitemid 40022247)
186. Hersh EM, O'Day SJ, Ribas A et al. A Phase II clinical trial of NAB-Paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 116(1), 155-163 (2010).
187. Kukowska-Latallo JF, Candido KA, Cao Z et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 65(12), 5317-5324 (2005). (Pubitemid 40827344)
188. Padilla De Jesus OL, Ihre HR, Gagne L, Frechet JMJ, Szoka FC. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconj. Chem.13(3), 453-461 (2002). (Pubitemid 34535938)
189. Tomalia DA, Reyna LA, Svenson S. Dendrimers as multipurpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem. Soc. Trans. 35(Pt 1), 61-67 (2007).
190. Konda SD, Wang S, Brechbiel M, Weiner EC. Biodistribution of a 153Gd-folate dendrimer, generation = 4, in mice with folate-receptor positive and negative ovarian tumor xenografts. Invest. Radiol. 37(4), 199-204 (2002). (Pubitemid 34259729)
191. Fukushima T, Takeshima H, Kataoka H. Antiglioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res. 29(11), 4845-4854 (2009)
192. Oda T, Sato F, Maeda H. Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH. J. Natl Cancer. Inst. 79(6), 1205-1211 (1987). (Pubitemid 18036723)
193. Wu G, Barth RF, Yang W et al. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconj. Chem. 15(1), 185-194 (2003). (Pubitemid 38165994)
194. Mross K, Niemann B, Massing U et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet™) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother. Pharmacol. 54(6), 514-524 (2004). (Pubitemid 40022247)
195. Hersh EM, O'Day SJ, Ribas A et al. A Phase II clinical trial of NAB-Paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 116(1), 155-163 (2010).
196. Kukowska-Latallo JF, Candido KA, Cao Z et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 65(12), 5317-5324 (2005). (Pubitemid 40827344)
197. Padilla De Jesus OL, Ihre HR, Gagne L, Frechet JMJ, Szoka FC. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconj. Chem.13(3), 453-461 (2002). (Pubitemid 34535938)
198. Tomalia DA, Reyna LA, Svenson S. Dendrimers as multipurpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem. Soc. Trans. 35(Pt 1), 61-67 (2007).
199. Konda SD, Wang S, Brechbiel M, Weiner EC. Biodistribution of a 153Gd-folate dendrimer, generation = 4, in mice with folate-receptor positive and negative ovarian tumor xenografts. Invest. Radiol. 37(4), 199-204 (2002). (Pubitemid 34259729)
200. Fukushima T, Takeshima H, Kataoka H. Antiglioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res. 29(11), 4845-4854 (2009).